Connect with us

Business

What should it take to convict a criminal?

Published

on

What should it take to convict a criminal?

The eviction of an intruder from my home was just the start of a long legal battle

Source link

Continue Reading
Advertisement
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

French-Gabonese artist Myriam Mihindou intertwines the personal and the political

Published

on

Sketch of a flower, made with blue ink on pale paper. The ink has been applied in such a way as to create scratches, distortions,  blotches and rivulets running down the paper

Unlock the Editor’s Digest for free

When Myriam Mihindou was in her 20s, she suffered from aphasia, an inability to speak or understand speech. The French-Gabonese artist’s process of rehabilitation helped her find her voice, both literally and artistically, and she has since developed a multidisciplinary practice in which collaboration plays a central role.

This autumn, a trio of major French exhibitions — at the Palais de Tokyo, the Musée du Quai Branly and the Biennale de Lyon — are set to solidify Mihindou’s reputation as a key figure in contemporary French and African diaspora art. But it was in 2000, when she created her first video installation, that she first struck upon her current mode of working. “I became conscious that I was a performance artist,” she says from her studio in Vitry-sur-Seine, a south-eastern suburb of Paris, dressed in a T-shirt and yoga trousers.

Advertisement

This early video, “Folle” (“Mad Woman”), is part of the artist’s new retrospective at the Palais de Tokyo, the French capital’s foremost contemporary art space. Projected on to the floor of the gallery, it shows Mihindou’s feet from a first-person perspective. The viewer hears laughing and jeering as her toes nervously explore the crack between two paving stones. After much hesitation, the feet leap from one stone to the next and the laughing stops. It’s a simple but potent visual metaphor for overcoming one’s fears.

Sketch of a flower, made with blue ink on pale paper. The ink has been applied in such a way as to create scratches, distortions,  blotches and rivulets running down the paper
‘Lingi’ (2022) by Myriam Mihindou © Pauline Guyon

Born in 1964 in Libreville, Gabon, to a French Catholic mother and a Gabonese animist, political activist father, Minhindou recalls her childhood as a rich source of inspiration, but also one of terror. “My father was often arrested,” she says. “He spent 14 years in prison for defending his political ideas.”

It was against the backdrop of her father’s opposition to the regime of President Omar Bongo Ondimba that Mihindou fled to France in the 1980s. In Bordeaux, she studied the architecture of the French colonial buildings that she had seen being razed. “When I was a child, the destruction of old colonial houses began,” she recalls. “In place of these houses, they built multistorey buildings, which drastically changed the atmosphere and the architectural memory of the neighbourhoods.” The destruction made her angry, she admits. “But I was able to separate the system from what that [same] system produced in terms of cultural heritage.”

Her studies did little to appease the pain of exile, however, and, to the dismay of her parents, Mihindou abandoned architecture to pursue a career in art. She enrolled in night courses at the University of Bordeaux, where a class on ruins provided the conceptual bridge between architecture and the internal conflicts that pressed her towards art-making. “I’m sort of obsessed with the idea of how to reconstitute the whole from a fragment,” she says. “Making things is, for me, a way of thinking through that.”

In 2004, Mihindou filmed “La Colonne Vide” (“The Empty Column”) in homage to her late sister. It shows a double image of the artist standing on a pedestal; as the figure on the right begins to move, walking backwards in a small circle, the one on the left follows with a few seconds of delay. Every so often, Mihindou stops to pose. She seems to represent herself and her sister as monuments of a very personal and individual kind. The subtle intertwining of personal story with political subtext is a recurring motif in her work.

Advertisement
A woman in a loose-fitting white long-sleeved T-shirt and matching white loose-fitting trousers dances on a platform. Her image is repeated so it looks like there are two identical women dancing together
A still from ‘La Colonne Vide’ (‘The Empty Column’) (2004) by Mihindou © Courtesy Myriam Mihindou et galerie Maïa Muller

It’s hard not to read these images against the context of ongoing debates regarding the presence of monuments to racist oppressors in public spaces. “I’m not an activist”, Mihindou insists at first, before conceding: “Alright. I am an activist when it comes to the question of pursuing certain goals. But I don’t like political structures. I don’t want to belong to a political movement or party.”

Themes of death and mourning are also present in her exhibition Ilimb, the Essence of Tears at Paris’s ethnographic Musée du Quai Branly. The show pays tribute to the Punu mourners of Gabon — an order of the ethnic group to which Mihindou belongs. In “Moñu” (2023), a long wickerwork braid snakes through the gallery; an embedded copper cord responds to the visitor’s touch, activating a sound recording of a Punu mourning ritual, guiding the souls of the deceased to the afterlife. Another work, “Nzumbili” (2023), presents what at first appear to be Gabonese wooden instruments, but which are actually trompe-l’oeil ceramic pieces. It both demonstrates Mihindou’s technical and conceptual sophistication and questions the museum’s conservation techniques and obsession with authenticity.

Photograph of an art exhibition containing a number of sculptural objects, including what looks like a long, thick rope made of wickerwork, snaking through the gallery on stands, and various three-dimensional sculptures on plinths
Mihindou’s installation at the Musée du Quai Branly © Musée du Quai Branly – Jacques Chirac, photo Thibaut Chapotot

While these works dialogue closely with the concerns and contradictions of a colonial trophy museum, the installation “Lève le doigt quand tu parles” (“Raise your hand when you speak”, 2023-24), which was presented at the 2024 Biennale de Lyon, touches on broader social concerns. Impaled on a scaffolding of metal rods, cement casts of women’s arms point towards the sky in a gesture that speaks to the making invisible of women’s roles and highlights their demand to be heard.

When I ask Mihindou about this piece, she reorients the question, preferring to tell me about the collaborative process of making it. “At first, it was tough, laborious,” she recalls. “The poor crew, I think they were cursing me. After a while, each found their place. Then, each person started to deploy their intelligence, to push forward in their own capacities. We were constantly inventing. When you start inventing, it’s moments of laughter and joy. Depending on what’s invented, you really discover personalities, and that’s very beautiful.”

Woman wearing a black top and black trousers
Myriam Mihindou, shot for the FT by Edouard Jacquinet at the Palais de Tokyo, Paris  © Photo by Edouard Jacquinet for the FT

Palais de Tokyo, October 17-January 5, palaisdetokyo.com. Musée du Quai Branly, to November 10, quaibranly.fr; La Biennale de Lyon, to January 5, labiennaledelyon.com

Source link

Advertisement
Continue Reading

Business

‘The beginning of the rebirth’

Published

on

Porcelain vase with a gilded base, coloured royal blue with a white diamond in the middle which has gold-leaf frame and features a painting of two cherubs in the centre

Unlock the Editor’s Digest for free

France’s flagship art and antiques fair has a chequered recent past. At one time the most glamorous fair in the world and an event of real cultural significance, the Biennale des Antiquaires has faced changing tastes, dipping attendance and a high-profile forgery scandal that rocked the French furniture trade. Reinvented as La Biennale, it merged with a younger initiative, Fine Arts Paris, in 2022, changing its name to FAB Paris the following year.

The event’s 100 or so exhibitors will convene this year under the great glass dome of the newly renovated Grand Palais (November 22-27). This return to the Biennale’s spectacular Art Nouveau home is, according to fair president Louis de Bayser, “the beginning of the rebirth”.

Advertisement

Unlike the extravaganzas staged in the 1980s and ’90s, the focus now, he maintains, is on the dealers and their objects rather than the mise en scène. At the same time, it is looking to the future and the next generation of dealers and, hopefully, also inspiring a new generation of collectors.

The two are not unrelated. “New dealers bring their own taste and a fresh perspective on handling works of art,” he explains. “Sometimes they bring collectors of their own generation.” In November, five emerging gallerists will contribute to a dedicated stand decorated by Victor Bonnivard, a young interior architect interested in combining the modern with the historical. Prices here will be under €25,000.

De Bayser describes the displays — and the fair itself — as an “invitation to become a collector”. Its two loan displays are aspirational as well as inspirational, and also dramatically contrasting. One represents — literally — the so-called “goût Rothschild” tradition of collecting the grandest of 17th- and 18th-century French furniture, boiserie, paintings, porcelain, tapestries and carpets.

Porcelain vase with a gilded base, coloured royal blue with a white diamond in the middle which has gold-leaf frame and features a painting of two cherubs in the centre
Vincennes vase made circa 1755 for Madame de Pompadour, the mistress of Louis XV, from the collection of Béatrice de Rothschild © Courtesy of Villa Ephrussi de Rothschild

It will feature 50 pieces from the vast and little-known collection amassed by the heiress Béatrice de Rothschild (1864-1934). Between 1907 and 1912, the Baroness created the magnificent Italianate mansion and gardens now known as the Villa Ephrussi de Rothschild, at Saint-Jean-Cap-Ferrat on the French Riviera. She bequeathed the villa and some 5,000 works of art from her numerous residences to the Académie des Beaux-Arts, including one of the most important collections of porcelain in France.

“Béatrice was an important figure in the art market during the first decade of the 20th century,” explains Oriane Beaufils, director of collections at the villa, which opened to the public in 1937. “She acquired works from legendary sales and from dealers whose descendants are still working in Paris.”

Advertisement

Despite her interest in the ancien régime, the Baroness’s collecting was eclectic, embracing early Italian paintings, Coromandel lacquer screens, and contemporary art. “She represents the crazy branch of Rothschild taste,” Beaufils enthuses. Among the loans there will be a 14th-century Sienese panel by Bartolo di Fredi, a Vincennes porcelain vase made for Madame de Pompadour and a 1904 Renoir — all set in an evocation of the villa’s opulent interiors by the acclaimed designer and collector Jacques Garcia.

The diversity and depth of Béatrice de Rothschild’s eye is relevant to a fair that offers everything from antiquities — among them an ancient Egyptian burial mask that once belonged to Coco Chanel — to Old Masters and modern art and design, by way of Asian and tribal art. Her eclecticism will also be echoed in the second display: a monumental, almost whimsical, “cabinet of curiosities” greeting visitors at the fair entrance.

Ancient Egyptian burial mask, looking like a very lifelike face sculpture, on a wooden plinth
Ancient Egyptian stucco burial mask, from Tuna el-Gebel, Antinopolis, circa 55-100 AD, formerly in the collection of Coco Chanel © Galerie Cybele

Here, the architect Sylvie Zerat has conceived an immersive installation featuring two 6.7-metre-long walls pierced by apertures of different scales and shapes. Inside will be 400 objects — from artists’ palettes and plaster casts to globes and reliquaries. Most are drawn from the collection of the illustrator, designer and owner of La Boutique, Marin Montagut. He describes them as “humble tokens of everyday life and folk art” found in flea markets and artisanal workshops. It is proof that collecting is not solely the preserve of Rockefellers or Rothschilds.

There is, however, ample opportunity to follow the Rothschilds’ lead. At Galerie Steinitz, a gilded bronze clock with painted glass panels by François Vion was reputedly a gift from Marie Antoinette and latterly in the collection of Baron Edouard de Rothschild (€650,000), while a set of three 18th-century, ormolu-mounted Chinese “clair de lune” celadon porcelain vases once belonged to Baron Guy de Rothschild (€1.2m). The Baron Alphonse is represented by a Japanese lacquer secretaire by Adam Weisweiler circa 1790-95, offered by Pascal Izarn.

Lavish trunk with four legs, largely made of lacquered wood but very heavily embellished and decorated with what looks like gold leaf or gold paint, including a textured disc on the side with what looks like a gold Roman coin
Japanese lacquer secretaire, made by Adam Weiseiler circa 1790-95, formerly in the collection of Baron Alphonse de Rothschild © Galerie Léage

De Bayser notes that the market for antique furniture remains a little subdued unless the pieces are of the very best quality or boast a sparkling provenance. Those looking for more contemporary inspiration, meanwhile, might find it at newcomers Maison Rapin, whose offering will include the likes of a coral and rock crystal chandelier made around 1980 by the late goldsmith and jeweller Robert Goossens.

“It takes time to build a new fair,” he concludes. Not every dealer invited to participate took up the invitation, and the proportion of foreign dealers is well below the 45 per cent of the Biennale’s heyday. Selection and vetting are key, he believes, as is the element of surprise. “We hope visitors will return year after year because they will never know what to expect.”

Advertisement

November 22-27, fabparis.com

Source link

Continue Reading

CryptoCurrency

BTC price eyes sub-$65K hurdles as metric hints Bitcoin 'going to rip'

Published

on

BTC price eyes sub-$65K hurdles as metric hints Bitcoin 'going to rip'


Bitcoin bulls enjoy more weekend BTC price gains as market cap signals point to a classic bull run comeback.



Source link

Advertisement
Continue Reading

CryptoCurrency

The Newest Artificial Intelligence Stock Has Arrived — and It Claims to Make Chips That Are 20x Faster Than Nvidia

Published

on

Motley Fool


The artificial intelligence chipmaker Nvidia (NASDAQ: NVDA) has amassed close to a $3.2 trillion market cap, making it one of the world’s largest chipmakers. It now consumes more than 6% of the broader benchmark S&P 500 index. Over the last five years, Nvidia has grown annual revenue by 458% and the stock is up an incredible 2,009%. Given the potential for AI to disrupt life as we know it, it’s understandable that investors are so excited about the stock.

But the lure of these kinds of gains is naturally going to attract competition. Now, one of Nvidia’s competitors is planning an initial public offering (IPO) and claiming to manufacture chips that can vastly outperform Nvidia at a fraction of the price. Let’s take a look.

20x better than Nvidia?

Last week, the AI chipmaker Cerebras filed its registration statement with the Securities and Exchange Commission (SEC) with the intent to go public. In a press release from 2021, Cerebras said it had a valuation of $4 billion after a $250 million series F financing round. The company is targeting a $1 billion IPO at a $7 billion to $8 billion valuation.

Advertisement

In its registration statement, Cerebras cites Nvidia as a competitor, as well as other large AI companies such as Advanced Micro Devices, Intel, Microsoft, and Alphabet. Here is a description of what Cerebras does:

We design processors for AI training and inference. We build AI systems to power, cool, and feed the processors data. We develop software to link these systems together into industry-leading supercomputers that are simple to use, even for the most complicated AI work, using familiar ML frameworks like PyTorch. Customers use our supercomputers to train industry-leading models. We use these supercomputers to run inference at speeds unobtainable on alternative commercial technologies.

Cerebras’ pitch is that bigger is better. That’s because the company has designed a chip that is the size of a full silicon wafer, and the largest ever sold. The company believes that the size advantage leads to less time moving data. Furthermore, Cerebras has a flexible business model in which clients can buy Cerebras products to have at their facilities or through a consumption-based subscription through the company’s cloud infrastructure.

Cerebras clearly wants investors to compare, or at least associate, the company with Nvidia. Nvidia is mentioned 12 times in the registration statement. Cerebras also provides a side-by-side comparison of its Wafer-Scale Engine-3 chip versus Nvidia’s H100 graphics processing unit (GPU), which is considered the most powerful GPU on the market.

Advertisement
Cerebras Nvidia comparison.

Image source: Cerebras registration statement.

Cerebras CEO Andrew Feldman publicly said the company’s inference offering is 20 times faster than Nvidia’s at a fraction of the price. In 2023, Cerebras generated about $78.7 million of revenue, up 220% year over year. Through the first half of 2024, Cerebras has grown revenue to $136.4 million. The company still hasn’t earned a profit, having reported a nearly $67 million loss through the first half of 2024. These numbers also pale in comparison to Nvidia, which recently reported second-quarter revenue of $30 billion and a profit of roughly $16.6 billion.

Will Cerebras make a splash?

With big publicity from news publications and claims of being 20 times faster than Nvidia, I think it’s safe to say that Cerebras already has and will continue to make a splash.

Depending on the excitement investment bankers can drum up during the company’s road show and market conditions, I wouldn’t be surprised to see Cerebras go public at a higher valuation than expected. AI has been all the buzz and the IPO market has been flat for a few years now, so there could be pent-up demand on Wall Street.

Will Cerebras overtake Nvidia? Only time will tell. Its product offerings are impressive, but it still has a ways to go to get its financial profile in line with Nvidia. Furthermore, there may be some advantages to Nvidia having smaller chips and it remains to be seen whether Cerebras can compete with Nvidia’s software language CUDA — although the company does say that its software program “eliminates the need for low-level programming in CUDA.”

Advertisement

While everything sounds great, there is likely still a “show me” component to this story. After all, the bulk of Cerebras’ revenue comes from one customer. Nvidia also has a leading market share in the AI chip space and relationships with many large clients. Who’s to say Nvidia couldn’t use its size — and likely resource — advantage to develop a similar large wafer chip? There’s a lot left to play out, but this could be one of the more interesting developments for market watchers to pay attention to.

Don’t miss this second chance at a potentially lucrative opportunity

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

  • Amazon: if you invested $1,000 when we doubled down in 2010, you’d have $21,266!*

  • Apple: if you invested $1,000 when we doubled down in 2008, you’d have $43,047!*

  • Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $389,794!*

Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.

Advertisement

See 3 “Double Down” stocks »

*Stock Advisor returns as of October 7, 2024

Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool’s board of directors. Bram Berkowitz has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Advanced Micro Devices, Alphabet, Microsoft, and Nvidia. The Motley Fool recommends Intel and recommends the following options: long January 2026 $395 calls on Microsoft, short January 2026 $405 calls on Microsoft, and short November 2024 $24 calls on Intel. The Motley Fool has a disclosure policy.

The Newest Artificial Intelligence Stock Has Arrived — and It Claims to Make Chips That Are 20x Faster Than Nvidia was originally published by The Motley Fool

Advertisement



Source link

Continue Reading

CryptoCurrency

Every AMD Stock Investor Should Keep an Eye on This Number

Published

on

Every AMD Stock Investor Should Keep an Eye on This Number


On some levels, Advanced Micro Devices (NASDAQ: AMD) looks increasingly like a competitor to Nvidia in the artificial intelligence (AI) accelerator market. While almost everyone perceives Nvidia as the dominant player in this market, AMD raised some eyebrows by winning a contract from Oracle.

Still, for all these accolades, AMD is barely profitable, and its revenue growth rate remains mired in the single digits. Also, despite the Oracle contract, AMD is not yet in Nvidia’s league regarding AI accelerators.

Nonetheless, one AMD metric has shown a dramatic improvement. As that figure continues to grow, the semiconductor stock could take its place as a full-fledged Nvidia competitor in the AI accelerator market.

Where investors should look

The important figure is not so much data center revenue as it is data center revenue as a percentage of total revenue. Here’s why: In the second quarter of 2024, AMD’s revenue of $5.8 billion grew by only 9% yearly. But this figure is deceiving. Gaming revenue dropped 59%, while embedded revenue fell 41%.

Advertisement

However, data center revenue, the segment designing AI accelerators, was up 115%! This is significant because Nvidia’s data center revenue was 88% of the company’s total in the latest quarter. Three years ago, it was not Nvidia’s largest revenue source. Now, the same pattern seems to have appeared in AMD’s financials.

In Q2, the data center was 49% of AMD’s revenue, up from only 25% one year ago. Assuming it is going to follow in Nvidia’s footsteps, AMD’s data center revenue appears on track to continue growing rapidly.

Furthermore, the chip industry is cyclical, meaning the gaming and embedded segments are unlikely to experience revenue declines comparable to the ones over the last year. Both factors should mean that AMD’s overall revenue — and, by extension, net income — are likely to experience dramatic surges, helping to draw more investors into AMD.

Ultimately, market leadership for AMD is unlikely anytime soon. However, as long as the data center segment continues to grow as a percentage of the company’s revenue, it should take its stock dramatically higher.

Advertisement

Don’t miss this second chance at a potentially lucrative opportunity

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

  • Amazon: if you invested $1,000 when we doubled down in 2010, you’d have $21,266!*

  • Apple: if you invested $1,000 when we doubled down in 2008, you’d have $43,047!*

  • Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $389,794!*

Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.

Advertisement

See 3 “Double Down” stocks »

*Stock Advisor returns as of October 7, 2024

Will Healy has positions in Advanced Micro Devices. The Motley Fool has positions in and recommends Advanced Micro Devices, Nvidia, and Oracle. The Motley Fool has a disclosure policy.

Every AMD Stock Investor Should Keep an Eye on This Number was originally published by The Motley Fool

Advertisement



Source link

Continue Reading

CryptoCurrency

2 Biotech Stocks That Are Screaming Buys This Month

Published

on

2 Biotech Stocks That Are Screaming Buys This Month


CRISPR Therapeutics (NASDAQ: CRSP) and Moderna (NASDAQ: MRNA) have much in common. They’re both innovative biotechs working in relatively newer niches of this booming industry.

However, they’ve moved in the wrong direction this year. CRISPR’s shares are down by 27% year to date, and Moderna’s are down by 41%. Regardless of their performances so far in 2024, both stocks are worth investing in this month. Read on to find out why.

1. CRISPR Therapeutics

CRISPR Therapeutics recently hit a breakthrough point when it earned approval for its first product, Casgevy, a therapy for sickle cell disease and transfusion-dependent beta-thalassemia. Casgevy is also the first medicine on the market that uses the famous CRISPR gene editing technique. Given this significant milestone, why is the company underperforming the market?

Here are two potential reasons. First, after Casgevy’s approval, some investors decided to take some profits. Second, it will take time before Casgevy contributes meaningfully to CRISPR Therapeutics’ financial results. Ex vivo gene editing medicines like Casgevy require that patients’ cells be collected and used to manufacture the treatment before it’s reinserted into them. The process takes a while and can only be done in qualified treatment centers.

Advertisement

Though it’s impossible to ignore these factors, investors may be undervaluing Casgevy’s prospects. CRISPR Therapeutics partnered with biotech giant Vertex Pharmaceuticals to develop and market it. As a result, the medicine earned approval in places a midcap biotech by itself may not have targeted: Saudi Arabia and Bahrain. These markets alone have some 23,000 eligible patients. The partners estimate an addressable market of 35,000 people in the U.S. and Europe.

Casgevy, at a price of $2.2 million in the U.S. — and very little competition to speak of, at least for now — could easily vastly exceed the $1 billion in sales milestone. Yes, it might take a little longer than it would if Casgevy were an oral pill, but patient investors should bide their time.

That’s why CRISPR Therapeutics is a great stock to buy this month. It hasn’t performed well this year, but over the long run, it has the tools to become a major player in the promising gene editing realm. Interested investors should scoop up the company’s shares while they’re down.

2. Moderna

Moderna made a name for itself during the pandemic by developing and marketing a successful COVID-19 vaccine. Although sales from this product have fallen off a cliff, the company has made plenty of progress.

Advertisement

Moderna is setting a solid foundation that could allow it to perform well over the long run. That starts with newer approvals: Moderna has now earned the green light for an RSV vaccine called mRESVIA and should launch at least one other product within the next couple of years.

The company’s combined coronavirus/flu vaccine aced a phase 3 study. It elicited higher immune responses than some individual vaccines in both categories in its late-stage trial.

Few people like getting shots, even if it’s necessary to do so. Getting one beats getting two, provided patients don’t have to sacrifice efficacy. It looks like that won’t be a problem.

Moderna has several other phase 3 candidates — a potential stand-alone flu vaccine, one for the cytomegalovirus (there currently is none), another for the norovirus, and still another that’s being developed as a personalized cancer vaccine in collaboration with Merck. Moderna should recover in time, even of its financial results currently don’t inspire confidence.

Advertisement

What does that mean for investors? The stock is down 41% year to date. There are several potential catalysts related to the company’s late-stage pipeline on the horizon that could jolt the stock price.

In the long run, Moderna’s vast pipeline of mRNA-based products should help it develop plenty of successful candidates. Now is a good time to buy.

Don’t miss this second chance at a potentially lucrative opportunity

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

Advertisement
  • Amazon: if you invested $1,000 when we doubled down in 2010, you’d have $21,266!*

  • Apple: if you invested $1,000 when we doubled down in 2008, you’d have $43,047!*

  • Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $389,794!*

Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.

See 3 “Double Down” stocks »

*Stock Advisor returns as of October 7, 2024

Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics, Merck, and Vertex Pharmaceuticals. The Motley Fool recommends Moderna. The Motley Fool has a disclosure policy.

Advertisement

2 Biotech Stocks That Are Screaming Buys This Month was originally published by The Motley Fool



Source link

Continue Reading

Trending

Copyright © 2024 WordupNews.com